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Background. The World Health Organization recently prequalified a typhoid conjugate vaccine (TCV), recommending its use 
in persons ≥6 months to 45 years residing in typhoid fever (TF)–endemic areas. We now need to consider how TCVs can have the 
greatest impact in the most vulnerable populations.
Methods. The Typhoid Fever Surveillance in Africa Program (TSAP) was a blood culture-based surveillance of febrile patients 
from defined populations presenting at healthcare facilities in 10 African countries. TF  and  invasive non-typhoidal Salmonella 
(iNTS) disease incidences were estimated for 0–10 year-olds in one-year age increments.
Results. Salmonella Typhi and iNTS were the most frequently isolated pathogens; 135 and 94 cases were identified, respectively. 
Analysis from three countries was excluded (incomplete person-years of observation (PYO) data). Thirty-seven of 123 TF cases 
(30.1%) and 71/90 iNTS disease cases (78.9%) occurred in children aged <5 years. No TF and 8/90 iNTS infections (8.9%) were 
observed in infants aged <9 months. The TF incidences (/100 000 PYO) for children aged <1 year and 1 to <2 years were 5 and 39, 
respectively; the highest incidence was 304 per 100 000 PYO in 4 to <5 year-olds. The iNTS disease incidence in the defined age 
groups ranged between 81 and 233 per 100 000 PYO, highest in 1 to <2 year-olds. TF and iNTS disease incidences were higher in 
West Africa.
Conclusions. High burden of TF detected in young children strengthens the need for TCV introduction. Given the concurrent 
iNTS disease burden, development of a trivalent vaccine against S. Typhi, S. Typhimurium, and S. Enteritidis may be timely in this 
region.
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The recently published multicenter Typhoid Fever Surveillance 
in Africa Program (TSAP) revealed a significant burden of inva-
sive Salmonella disease in sub-Saharan Africa [1]. These data 
largely confirmed estimates generated by two recent systematic 
reviews [2, 3] and suggested that the burden of typhoid fever in 
parts of sub-Saharan Africa is increasing [2]. Correspondingly, 
the relative contribution of Salmonella as an agent of invasive 
disease is rising, contrasting the dramatic reduction of invasive 
bacterial disease caused by Haemophilus influenzae type b and 
Streptococcus pneumoniae in African infants, a consequence of 
routine immunization against these pathogens. Such immu-
nization programs are not yet available to prevent invasive 
Salmonella disease.
Salmonella enterica serovar Typhi (S. Typhi) causes typhoid 
fever, and the S. enterica serovar Paratyphi A (less commonly 
B and C) causes the clinically indistinguishable disease para-
typhoid fever. Infection with other Salmonella serovars, the 
nontyphoidal Salmonella (NTS) serovars, generally result in 
a self-limiting diarrhea. However, NTS organisms can also 
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induce a systemic infection in susceptible individuals, result-
ing in invasive NTS (iNTS) disease [4]. Globally, typhoid fever 
and iNTS disease are estimated to be responsible for 20.6 and 
3.4 million illnesses and 223 000 and 681 000 deaths annually, 
respectively [3, 5–7].
Presently, there are three typhoid vaccines available: (1) an 
injectable polysaccharide vaccine composed solely of purified 
Vi antigen (ViPS vaccine), which is licensed for adults and chil-
dren aged ≥2 years; (2) a live attenuated oral vaccine available 
in capsular formulation, licensed for adults and children aged 
≥5 years (Ty21a); and (3) a recently licensed typhoid conjugate 
vaccine (TCV), comprising of Vi antigen covalently linked to 
a carrier protein. The TCV elicits sustained immunoglobulin 
G anti-Vi response after single-dose administration to infants, 
toddlers, and older age groups [8, 9]. 
The efficacy of the ViPS and Ty21a vaccines is approximately 
70% at 3  years after immunization and about 60% for Ty21a 
7 years after immunization [10]. The ViPS vaccine is safe, well 
tolerated, but weakly immunogenic in infants, with antibody 
titers being only short-lived [10–12]; Ty21a is not licensed for 
use in preschool children, infants, or toddlers. These particular 
properties, in addition to limited global production capacity, ren-
der these two vaccines ineligible for Gavi subsidy in developing 
countries. The World Health Organization (WHO) has recom-
mended vaccination with a single dose of TCV in children from 
6 months of age to adults up to 45 years of age living in areas 
where typhoid fever is endemic, with an emphasis on introduc-
tion alongside other Expanded Program on Immunization (EPI) 
vaccines at 9 months or in the second year of life [13].
Data have existed for approximately 20 years showing that 
a TCV, consisting of Vi linked to exotoxin A of Pseudomonas 
aeruginosa (Vi-rEPA), was immunogenic in preschool children 
and young infants (with doses given at 2, 4, and 6 months of 
age). Furthermore, two doses of Vi-rEPA conferred 89% pro-
tection over 46 months in 2-4-year-old Vietnamese children in 
a randomized controlled trial. That study generated substantial 
anticipation that Vi-rEPA (and other TCVs) would be licensed 
and prequalified in a reasonable time frame [14]. However, 
it was not until the end of 2017 that a TCV, Typbar-TCV®, 
 manufactured by Bharat Biotech International and licensed 
by the Indian National Regulatory Agency, was recommended 
by the Scientific Advisory Group of Experts (SAGE) for use in 
infants, toddlers, and older persons [15]. In 2018, the vaccine 
was prequalified by the WHO, making it eligible for United 
Nations agencies procurement and Gavi support [16].
In a randomized, placebo-controlled human volunteer chal-
lenge study, Typbar-TCV® conferred protection against 54.6% 
(95% confidence interval [CI], 26.8%–71.8%) of typhoid fever 
infections when the primary endpoint was defined as fever of 
≥38.0°C for ≥12 hours or S. Typhi bacteremia. Using an alter-
native endpoint of S. Typhi bacteremia after fever of ≥38.0°C, 
the vaccine efficacy of Typbar-TCV® was 87.1% (95% CI, 
47.2%–96.9%), compared with 52.3% (95% CI, –4.2% to 78.2%) 
for ViPS for the same endpoint [17]. Phase III and IV trials are 
planned in endemic countries, and manufacturers are devel-
oping other TCV candidates [18, 19]. Although the TCVs are 
effective only against S. Typhi, several vaccines against iNTS 
disease are at an early stage of development, some of which 
are bivalent, targeting both S. enterica serovars Enteritidis and 
Typhimurium [20, 21]. A typhoid fever/iNTS disease conjugate 
vaccine targeting S. Enteritidis, S. Typhimurium, and S. Typhi is 
commencing phase 1 clinical trials in 2018 [22].
With a first TCV now available for procurement and Gavi 
subsidy, and with a battery of prospective vaccines in the pipe-
line, relevant epidemiological data are needed to inform deci-
sion making regarding vaccine target groups and introduction 
strategies. A detailed understanding of typhoid fever hot spots 
and disease in infants and young children are important for 
identifying the most effective vaccination strategy. Furthermore, 
the feasibility of introducing TCV into the existing EPI needs 
to be considered alongside priorities of targeting children early 
enough to prevent infection in infancy. Here, we reanalyze the 
data obtained through the TSAP to obtain incidences in the 
children <5 years old by yearly age increments and stratify them 
by different African regions.
METHODS
To understand the occurrence of invasive Salmonella disease in 
infants and young children, we conducted further analysis using 
recently published TSAP disease incidence data [1], stratifying 
by 12-month age increments for children aged 0–10 years of age 
(Table 1) and by region, East versus West African TSAP study 
sites (Table 2). Briefly, the TSAP study performed blood cul-
ture-based surveillance in febrile persons presenting at health-
care facilities in 10 countries: Burkina Faso (2 sites), Ethiopia, 
Ghana, Guinea-Bissau, Kenya, Madagascar (2 sites), Senegal, 
South Africa, Sudan, and Tanzania (2 sites) [1, 23]. 
Patients of all ages (except in Ghana where only children 
aged <15 years were enrolled) with acute fever (≥37.5°C axillary 
or ≥38.0°C tympanic) or history of fever (≥3 consecutive days 
in the past 7 days) attending healthcare facilities in a defined 
catchment area were enrolled, and blood samples were taken 
to isolate bacterial pathogens. In total, 13 431 blood samples 
were assessed, from which 568 were positive yielding non-con-
taminant isolates. The most commonly isolated non-contami-
nant pathogens were S. Typhi (135; 23.8%), iNTS (94; 16.5%), 
Staphylococcus aureus (70; 12.3%), E. coli (47; 8.3%), and S. pneu-
moniae (43; 7.6%); 179 other non-contaminant pathogens 
(31.5%) were identified in lower frequencies (ie, Klebsiella pneu-
moniae and oxytoca, Acinetobacter spp., Enterobacter spp., and 
Pseudomonas spp.). The proportion of contaminated blood cul-
tures was highest in Burkina Faso reaching 24% in one site, 12% 
in Guinea-Bissau, and <10% in the remaining settings presented 
here [1]. Burkina Faso, Ghana, Guinea-Bissau represented West 
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Africa; Kenya, Tanzania, Sudan, and Madagascar, East Africa. 
Ethiopia, South Africa, and Senegal were excluded, owing to the 
absence of person-years of observation (PYO) data from these 
sites. 
To evaluate the disease burden across all TSAP sites, we 
deployed a Poisson model that was adjusted for site as a random 
effect. This approach was used to estimate the incidences of S. 
Typhi and iNTS disease in each of the age strata. In addition, a 
stratified Poisson model was fitted to estimate disease incidences 
in the various age groups in each region (GLIMMIX in SAS soft-
ware; version 9.4; SAS Institute). This model was then used to gen-
erate pan-African and regional (East and West Africa) incidence 
estimates. The ethics committees of all collaborating institutions 
at the TSAP sites and that of the International Vaccine Institute 
(Seoul, Republic of Korea) approved the TSAP study protocol.
RESULTS
Overall age data from all 10 countries showed S. Typhi and NTS 
to be the most frequently identified non-contaminant organ-
isms, with a total of 135 and 94 isolations, respectively [1]. After 
exclusion of 12 typhoid fever and 4 iNTS disease isolates from 
Ethiopia, South Africa, and Senegal owing to the absence of PYO 
data, 37 (30.1%) of 123 cases of typhoid fever and 71 (78.9%) of 
90 cases of iNTS occurred in children aged <5 years (Table 1). 
No cases of typhoid fever and 8 (8.9%) of 90 iNTS infections 
were observed in infants aged <9 months (Figure 1). Of the 37 
children with typhoid fever, 17 (46.0%) were hospitalized; 58 
(81.7%) of the 71 children with iNTS disease were hospitalized. 
This disparity in hospitalization rates was significant (P < .001; 
χ2-test) but did not remain significant after adjustment for age 
(maximum likelihood estimation; P  =  .07). Expanding these 
analyses to all age groups, 38 (30.9%) of 123 patients with 
typhoid fever and 68 of 90 (75.5%) with iNTS were hospitalized 
(maximum likelihood estimation; P = .047).
Our data demonstrated that typhoid fever was most common 
in children aged 2 to <8 years, whereas iNTS disease peaked 
in children aged <5 years, particularly in those aged <2 years 
(Figure  1). The annual typhoid fever incidences (per 100 000 
PYO) for children aged <1 year and 1 to <2 years were 5 and 
39, respectively. The age group with the highest typhoid fever 
incidence (304/100 000 PYO) was 4 to <5 years (Table 1); the 
age group with the highest iNTS incidence (233/100 000 PYO) 
was 1 to <2 years (Table 1).
After stratifying surveillance sites by geographic location (East 
vs West Africa) (Table  2), we observed a significant difference 
in disease incidence between the two regions (P =  .009; χ2 test). 
Notably, the annual incidences of typhoid fever and iNTS disease 
were higher in the West African than in the East African sites 
(Figure 2). The cumulative incidence of typhoid fever in children 
aged <5 years, per 100 000 PYO, was 279 in West Africa, compared 
with 154 in East Africa. The iNTS incidence in the same age group, 
per 100 000 PYO, was 828 in West and 48 in East Africa (Figure 2).
Table  1. Incidence of Invasive Salmonella Infections in Children and Adults Enrolled in the Typhoid Surveillance in Africa Program, March 2010 to 
January 2014a
Age Group, y 
Patients Enrolled, 
No. PYOb
Salmonella Typhi iNTS Disease
Crude Cases, 
No.
Cases Adjusted for 
Recruitment, No.c
Adjusted Incidence 








100 000 PYO  
(95% CI)
0 to <1 1217 8658 1 1 5.4 (.6–47.3) 14 (15)d 33 81.4 (27.4–241.6)
1 to <2 1057 9102 4 7 39.4 (12.3–125.9) 27 77 233.2 (81.5–667.6)
2 to <3 818 6407 7 19 152.7 (56.3–413.9) 13 35 138.7 (47.0–409.2)
3 to <4 685 5507 13 27 239.6 (91.1–630.4) 15 38 206.3 (70.4–603.9)
4 to <5 575 4800 12 (16)d 28 304.1 (116.4–794.3) 2 8 46.2 (13.0–164.1)
5 to <6 427 13 638 7 13 56.8 (20.0–161.4) 4 8 18.4 (5.3–63.8)
6 to <7 356 8277 6 (10)d 17 87.7 (31.9–241.7) 1 4 11.2 (2.7–46.6)
7 to <8 376 16 594 11 (12)d 21 111.0 (41.4–297.8) 2 6 19.5 (5.5–69.3)
8 to <9 310 10 047 9 16 116.3 (42.2–320.6) 1 3 12.0 (2.6–55.6)
9 to <10 254 9019 4 (5)d 8 70.3 (23.3–212.5) 2 6 30.8 (8.7–109.5)
10 to <15 1004 23 977 26 (27)d 42 109.8 (43.1–279.6) 3 7 11.1 (3.1–39.2)
15 to <20 566 14 283 7 (8)d 10 57.3 (19.4–168.9) 1 3 15.9 (3.5–73.4)
20 to <35 1465 48 352 13 (16)d 21 38.2 (14.3–101.9) 1 4 5.2 (1.2–21.5)
≥35 1288 34 576 3 3 8.8 (2.1–37.1) 4 (5)d 6 13.8 (3.8–50.1)
Total 10 398 213 241 123 (138)d 233 90 (92)d 239
Abbreviations: CI, confidence interval; iNTS, invasive nontyphoidal Salmonella; PYO, person-years of observation.
aEthiopia, South Africa, and Senegal were excluded from the analysis because no PYO data were available.
bStudy population adjusted for healthcare-seeking behavior.
cCrude cases adjusted for recruitment proportion (No. of patients analyzed/No. with febrile illness from study area who visited a recruitment health facility × 100.)
dCrude cases adjusted for recruitment pattern unique to the site in Tanzania: before 11 November 2011 every fifth eligible patient was recruited, and from 11 November 2011 every second 
eligible patient was recruited. Adjusted cases (presented parenthetically) were used to calculate crude rates. 
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DISCUSSION
The data evaluated here are the first systematically collected 
multisite incidence data for typhoid fever and iNTS in young 
children in Africa, which provides evidence of a substantial 
typhoid fever burden that merits vaccine use. Our findings on 
typhoid fever burden are largely consistent with recent disease 
burden estimates [2]. A high incidence of typhoid fever in chil-
dren aged 2 to <4 years has been recorded in previous studies 
in Kenya [24] and India [25], and similar results have also been 
obtained from Vietnam [26] and Bangladesh [27]. The “Diseases 
of the Most Impoverished” program provided data for children 
<2 years of age in two countries, India and Indonesia, and found 
that the burden of typhoid fever in this age group was compara-
tively low [28]. In contrast, iNTS disease seems to affect mainly 
individuals in sub-Saharan Africa, and its geographic range cor-
relates with the occurrence of malaria [29].
The delay of a WHO-prequalified TCV resulted in many years 
of sparse use of typhoid vaccines in endemic areas, because the 
existing vaccines were not eligible for Gavi subsidy and only one 
vaccine manufacturer had a WHO-prequalified product. The 
recent availability of the first WHO-prequalified TCV and the 
specific SAGE recommendations constitute a potential turning 
point. Existing vaccine policies are being reassessed, and it is 
paramount to identify the optimum time of administration for 
the effective integration of typhoid vaccines into existing vac-
cination programs. Based partly on the data presented here, 
SAGE recently recommended the use of TCVs in children aged 
<2 years and proposed further disease surveillance to identify 
high-risk areas [15].
We found that children aged <5 years bear the highest bur-
den of typhoid fever and iNTS infections and that West African 
TSAP sites had a higher disease burden than East African TSAP 
Figure 1. Frequency of Salmonella Typhi (left) and invasive nontyphoidal Salmonella (iNTS) (right) infections in children <5 years of age enrolled in the Typhoid Surveillance 
in Africa Program (TSAP) from March 2010 to January 2014.
Table 2. Incidence of Invasive Salmonella Infections in Children and Adults, by Region (East and West), Enrolled in the Typhoid Fever Surveillance in 
Africa Program, March 2010 to January 2014a 
Age Group, y
Salmonella Typhi Incidence/100 000 PYO iNTS Disease Incidence/100 000 PYO
East African Region West African Region East African Region West African Region
0–1 to <1 41.4 (5.7–300.6) 0 165.6 (61.5–446.3) 464.5 (321.5–671.3)
1 to <2 65.8 (16.2–267.2) 82.5 (34.0–200.2) 32.9 (4.5–238.7) 1253.8 (998.8–1573.9)
2 to <3 45.5 (6.3–330.6) 427.5 (267.9–682.1) 0 831.2 (594.6–1162.1)
3 to <4 205.3 (84.6–498.2) 683.7 (443.6–1053.8) 41.1 (5.7–298.1) 1204.6 (869.6–1668.7)
4 to <5 457.1 (244.2–855.6) 689.0 (431.8–1099.3) 0 267.9 (126.7–566.8)
5 to <6 51.7 (19.2–139.4) 152.4 (78.7–295.2) 12.9 (1.8–93.9) 118.6 (56.0–250.8)
6 to <7 222.3 (110.3–448.1) 192.4 (99.3–372.5) 0 85.5 (31.7–230.4)
7 to <8 67.2 (33.3–135.4) 277.4 (160.1–480.7) 0 149.4 (70.6–316.0)
8 to <9 75.9 (31.3–184.2) 318.0 (174.9–578.2) 0 86.7 (27.6–272.4)
9 to <10 63.8 (23.7–171.8) 182.0 (75.0–441.6) 0 254.8 (120.4–538.9)
10 to <15 141.8 (92.0–218.6) 228.9 (148.5–352.9) 0 76.3 (36.1–161.4)
15 to <20 104.9 (52.1–211.5) 30.0 (7.4–122.0) 0 45.1 (14.3–141.5)
20 to <35 90.7 (55.2–148.8) 16.3 (6.7–39.5) 0 13.0 (4.8–35.1)
≥35 15.6 (5.0–49.0) 0 31.2 (13.9–70.1) 0
Abbreviations: iNTS, invasive nontyphoidal Salmonella; PYO, person-years of observation.
aWest African countries included Ghana, Burkina Faso, and Guinea-Bissau; East African countries, Kenya, Tanzania, Sudan, and Madagascar.
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sites. Independent of the investigated sites in both African 
regions, our data suggest that there is a high burden of typhoid 
fever in children aged <5 years, affecting children as young as 9 
months of age. These findings are aligned with the recommen-
dation to introduce TCV at 9 months [13], in order to ensure 
maximum protection of the at risk population and slow the 
increase of multidrug-resistant Salmonella. Coadministration 
of TCV with the first dose of measles vaccine at age 9 months 
may be a practical approach [9]. For example, our data demon-
strate that a vaccine against both typhoid fever and iNTS dis-
ease administered at 9 months of age would have been delivered 
before 100% (all 123) of the typhoid fever infections and 95.5% 
(86 of 90) of the iNTS disease infections occurred in the TSAP. 
Therefore, even a vaccine with a lower efficacy and a shorter 
duration of protection would have measurable impact on 
disease at a young age and may allow for boosting at a later 
stage. (Figure 1). Given that S. Typhi, a pathogen restricted to 
humans, is now appropriate for effective prevention through 
vaccination at age 9 months, in accordance with recent WHO 
recommendations [13], TCV should be introduced in high-risk 
areas without further delay.
For iNTS disease, we encourage the development of iNTS 
conjugate vaccines targeting S. Typhimurium/S. Enteritidis 
serovars that could be prioritized in malaria-endemic areas 
of Africa or, potentially, a combinatory trivalent (S. Typhi/S. 
Typhimurium/S. Enteritidis) vaccine to comprehensively tackle 
the invasive Salmonella disease [22]. Given that about 10% of 
iNTS infections occur in children aged <9 months, a future iNTS 
vaccine may need to be introduced at an earlier EPI time point. 
This could potentially be coupled with maternal vaccination 
Figure 2. Incidence of invasive Salmonella infections in children by region (West and East) from the Typhoid Surveillance in Africa Program, March 2010 to January 2014. 
A, Salmonella Typhi infections. B, Invasive nontyphoidal Salmonella (iNTS) infections. West African countries included Ghana, Burkina Faso, and Guinea-Bissau; East African 
countries, Kenya, Tanzania, Sudan, and Madagascar. Abbreviation: PYO, person-years of observation.
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before childbirth, as done for other vaccines [30]; however, more 
data are required to substantiate this approach for iNTS disease. 
Consequently, the most likely scenario would be to deploy TCV 
for the prevention of typhoid fever at 9 months of age and pursue 
the development of an iNTS vaccine to be administered earlier 
within the current EPI program to tackle iNTS disease.
In addition to the limitations previously outlined for the 
TSAP study [1], it is important to address the difficulties 
encountered when obtaining blood samples from infants and 
young children. The volume of blood collected during TSAP 
was often lower (<1 mL) than recommended by manufacturers 
of analytical devices, and a higher proportion of contamination 
was observed in children than in adults. These issues may have 
reduced the ability to detect pathogenic bacteria, including both 
S. Typhi and iNTS disease. The relatively low burden of S. Typhi 
in the blood of patients with bacteremia could also result in an 
underestimation of S. Typhi in the very young age group [31]. It 
is also important to note that the differences observed between 
West and East African sites were estimated only within TSAP 
sites, and further studies in other regions of Africa, particularly 
rural settings, are required to confirm this finding.
In conclusion, this analysis of the occurrence of invasive 
Salmonella in children aged <5 years provides evidence of the 
high burden of typhoid fever in Africa and complements data 
presented at the recent SAGE meeting, much of which was 
reflected in a position taken by the WHO in 2018 [13, 15]. The 
TCVs are now recommended for use in children aged <2 years, 
and there is a WHO-prequalified TCV in place for use. The high 
burden of typhoid fever in the TSAP sites merits introduction 
of TCV at age 9 months, coinciding with the first measles vac-
cine dose. This strategy would have permitted vaccine delivery 
ahead of all S. Typhi infections identified in TSAP. The evidence 
presented here also highlights a significant burden of iNTS 
infections in children aged <5 years, a burden that will persist 
beyond TCV introduction until a safe and effective and iNTS 
vaccine is introduced in immunization programs. Considering 
the high incidence of typhoid fever and iNTS disease, the 
development and introduction of a trivalent vaccine against S. 
Typhi, S. Typhimurium, and S. Enteritidis may be a solution for 
comprehensively addressing the burden of invasive Salmonella 
infections in Africa.
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